This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Scagnolari, C. Articles by Antonelli, G. Search for Related Content PubMed PubMed Citation Articles by Scagnolari, C. Articles by Antonelli, G.

Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia

Department of Experimental Medicine, Virology Section,¹ Department of Clinical Medicine, Policlinico Umberto I,² Department of Experimental Medicine, University "La Sapienza",³ "Campus Biomedico," Libera Università, Rome, Italy⁴

Received 28 March 2002/ Returned for modification 11 August 2002/ Accepted 5 October 2002

The efficacy of alpha interferon (IFN-) in the treatment of severe type II essential mixed cryoglobulinemia (EMC) has been reported previously. In some patients, the development of neutralizing antibodies to recombinant IFN- (rIFN-) can affect the clinical response achieved with rIFN-; a second treatment with natural IFN- preparations may reinduce the clinical response. In the present study the ability of leukocyte IFN (LeIFN) to restore the response was investigated from a pharmacodynamic viewpoint. Specifically, the pharmacodynamic profiles of different IFN- preparations were studied by measuring the serum neopterin levels and the levels of expression of protein MxA mRNA in in vivo peripheral blood mononuclear cells in two patients with EMC whose resistance to rIFN-2a treatment increased concomitantly with the development of neutralizing antibodies. These markers were measured before injection and at 24 and 48 h after a single injection of rIFN-2a, consensus IFN [(C)IFN], or LeIFN. No increase or only a slight increase in MxA mRNA levels was detectable after administration of rIFN-2a or (C)IFN, whereas a significant increase (10-fold) in MxA mRNA expression was recorded following administration of LeIFN. The neutralizing antibodies to rIFN-2a cross-react with (C)IFN. Sera from these patients neutralized most but not all of the subtypes present in the natural IFN- (LeIFN) mixture, and no significant increase in neopterin levels was observed after these patients were switched to LeIFN treatment. In summary, the data demonstrate that the problem of neutralizing antibodies still exists and that LeIFN may induce an increase in the level of MxA mRNA expression but not an increase in neopterin levels in patients who are resistant to treatment with rIFN-2a or (C)IFN.